Review Article
Volume 8 Issue 2 - 2021
Causes, Consequences, and Cures of Clostridium difficile Infection
Nicholas A Kerna1,2*, John V Flores3,4, Hilary M Holets3,4, Lawrence U Akabike5, Mark H Chen6, Emmaneulla Olubumni Solomon7, Kevin D Pruitt8, Uzoamaka9 and Shain Waugh10
11SMC–Medical Research, Thailand
2First InterHealth Group, Thailand
3Beverly Hills Wellness Surgical Institute, USA
4Orange Partners Surgicenter, USA
5Larrico Enterprises, LLC, USA
6For Your Health, LLC, USA
7Obafemi Awolowo University, Nigeria
8Kemet Medical Consultants, USA
9University of Washington, USA
10Fettle Path, USA
*Corresponding Author: Nicholas A Kerna, (mailing address) POB47 Phatphong, Suriwongse Road, Bangkok, Thailand 10500. Contact: medpublab+drkerna@gmail.com.
Received: December 28, 2020 Published: Janaury 30, 2021




Abstract

C. difficile infection (CDI) is distinctly associated with antibiotic use and the foremost cause of healthcare-associated infective diarrhea. The bacterial spores are primarily transmitted through the fecal-oral route. Worldwide, CDI affects about 8/100,000 individuals each year; the hospitalized population affected is about 4–8/1000 people), causing about 29,000 deaths in the United States alone; and affects about half a million people globally in 2011. In hospital settings, the spores are typically transmitted from the hands of healthcare workers to patients and vice versa. Risk factors for acquiring a C. difficile infection include exposure to most antibiotics, old age (although the younger population can be affected), and immunocompromised or hospitalized patients. The clinical presentation of CDI varies, from asymptomatic carriers to patients with life-threatening colitis. Patients with CDI may present with diarrhea, intense abdominal pain, fever, nausea, weakness, and decreased appetite or anorexia. Although active gastrointestinal bleeding is infrequent, fecal occult blood is positive in specific patients. The most severe form of CDI can lead to dehydration, abdominal distention, hypoalbuminemia, toxic megacolon, colon perforation, intestinal paralysis, kidney failure, septicemia, shock, and death. Most CDI cases are self-limiting with antibiotic therapy withdrawal or vancomycin/fidaxomicin/metronidazole therapy. However, in some patients, CDI can lead to complications requiring surgical intervention. In severe recurrent cases, fecal microbiota transplantation (FMT) is a promising treatment option. The preferred approach concerning CDI is contamination prevention rather than treating active CDI. Regular hand hygiene and other proactive sanitary measures are deemed simple yet effective measures in preventing C. difficile infection.

 

Keywords: Colitis; Community-Acquired; Enterohemorrhagic; Gastrointestinal; Ileus; Microflora; Nosocomial

References

    1. Oren A and Garrity GM. “List of new names and new combinations previously effectively, but not validly, published”. International Journal of Systematic and Evolutionary Microbiology 67 (2017): 3140-3143. https://www.microbiologyresearch.org/content/journal/ijsem/10.1099/ijsem.0.003991
    2. Lawson PA., et al. “Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Preevot 1938”. Anaerobe 40 (2016): 95-99. https://pubmed.ncbi.nlm.nih.gov/27370902/
    3. Hall IC and O'Toole E. “Intestinal flora in newborn infants with description of a new pathogenic anaerobe”. The American Journal of Diseases of Children 49 (1935): 390-402. https://jamanetwork.com/journals/jamapediatrics/article-abstract/1176814
    4. Tedesco FJ., et al. “Clindamycin-associated colitis. A prospective study”. Annals of Internal Medicine 81 (1974): 429-433. https://pubmed.ncbi.nlm.nih.gov/4412460/
    5. Leffler DA and Lamont JT. “Clostridium difficile infection”. The New England Journal of Medicine 373 (2015): 287-288. https://pubmed.ncbi.nlm.nih.gov/25875259/
    6. Martin JS., et al. “Clostridium difficile infection: epidemiology, diagnosis and understanding transmission”. Nature Reviews Gastroenterology and Hepatology 4 (2016): 206-216. https://pubmed.ncbi.nlm.nih.gov/26956066/
    7. Bouwknegt M., et al. “Burden of Clostridium difficile infection in the United States”. The New England Journal of Medicine 24 (2015): 2368. https://www.nejm.org/doi/full/10.1056/NEJMoa1408913
    8. Hensgens MP., et al. “Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics”. Journal of Antimicrobial Chemotherapy 67 (2012): 742-748. https://pubmed.ncbi.nlm.nih.gov/22146873/
    9. Czepiel J., et al. “Epidemiology of Clostridium difficile infection: results of a hospital-based study in Krakow, Poland”. Epidemiology and Infection 143 (2015): 3235-3243. https://www.researchgate.net/publication/274893683_Epidemiology_of_Clostridium_difficile_infection_Results_of_a_hospital-based_study_in_Krakow_Poland
    10. Khanna S., et al. “The epidemiology of community-acquired Clostridium difficile infection: a population based study”. The American Journal of Gastroenterolog 107 (2012): 89-95. https://pubmed.ncbi.nlm.nih.gov/22108454/
    11. Loo VG., et al. “Host and pathogen factors for Clostridium difficile infection and colonization”. The New England Journal of Medicine 365 (2011): 1693-1703. https://www.nejm.org/doi/full/10.1056/NEJMoa1012413
    12. Hensgens MPM., et al. “Clostridium difficile infection in the community: a zoonotic disease?” Clinical Microbiology and Infection 18 (2012): 635-645. https://www.sciencedirect.com/science/article/pii/S1198743X14645584
    13. Johnson S., et al. “Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission”. The American Journal of Medicine 88 (1990): 137-140. https://europepmc.org/article/med/2301439
    14. Simor AE. “Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review”. Journal of the American Geriatrics Society 58 (2010): 1556-1564. https://pubmed.ncbi.nlm.nih.gov/20646106/
    15. Kyne L., et al. “Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea”. Infection Control and Hospital Epidemiology 23 (2002): 653-659. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/underlying-disease-severity-as-a-major-risk-factor-for-nosocomial-clostridium-difficile-diarrhea/51CC25F15D1B51D83E54D3EDD98BBAF5
    16. Chitnis AS., et al. “Epidemiology of community associated Clostridium difficile infection, 2009 through 2011”. JAMA Internal Medicine 173 (2013): 1359-1367. https://pubmed.ncbi.nlm.nih.gov/23780507/
    17. Novack L., et al. “Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias”. PLoS One 9 (2014): e110790. https://pubmed.ncbi.nlm.nih.gov/25343667/
    18. Kochan TJ., et al. “Intestinal calcium and bile salts facilitate germination of Clostridium difficile spores”. PLOS Pathogens 13 (2017): e1006443. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006605
    19. Chiang JY. “Bile acids: regulation of synthesis”. Journal of Lipid Research 50 (2009): 1955-1966. https://pubmed.ncbi.nlm.nih.gov/19346330/
    20. Francis MB., et al. “Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection”. PLOS Pathogens 9 (2013): e1003356. https://pubmed.ncbi.nlm.nih.gov/23675301/
    21. Allegretti JR., et al. “Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles”. Alimentary Pharmacology and Therapeutics 43 (2016): 1142-1153. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214573/
    22. Baktash A., et al. “Mechanistic insights in the success of fecal microbiota transplants for the treatment of Clostridium difficile infections”. Frontiers in Microbiology 9 (2018): 1242. https://pubmed.ncbi.nlm.nih.gov/29946308/
    23. Smits WK., et al. “Clostridium difficile infection”. Nature Reviews Disease Primers 2 (2016): 16020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453186/
    24. Lyerly DM., et al. “Effects of Clostridium difficile given intragastrically to animals”. Infection and Immunity 47 (1985): 349-352. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC263173/
    25. Savidge TC., et al. “Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine”. Gastroenterology 125 (2003): 413-420. https://pubmed.ncbi.nlm.nih.gov/12891543/
    26. McDonald LC., et al. “An epidemic, toxin-gene variant strain of Clostridium difficile”. The New England Journal of Medicine 353 (2005): 2433-2441. https://pubmed.ncbi.nlm.nih.gov/16322603/
    27. Loo VG., et al. “A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality”. The New England Journal of Medicine 353 (2005): 2442-2449. https://pubmed.ncbi.nlm.nih.gov/16322602/
    28. Rocha MFG., et al. “Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin- 1β, tumor necrosis factor alpha, and leukotrienes”. Infection and Immunity 65 (1997): 2740-2746. https://pubmed.ncbi.nlm.nih.gov/9199444/
    29. McDonald LC., et al. “Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)”. Clinical Infectious Diseases 66 (2018): e1-e48. https://pubmed.ncbi.nlm.nih.gov/29462280/
    30. Vincent JL., et al. “International study of the prevalence and outcomes of infection in intensive care units”. The Journal of the American Medical Association 302 (2009): 2323-2329. https://pubmed.ncbi.nlm.nih.gov/19952319/
    31. McFarland LV. “Antibiotic-associated diarrhea: epidemiology, trends and treatment”. Future Microbiology 3 (2008): 563-578. https://pubmed.ncbi.nlm.nih.gov/18811240/
    32. Fekety R., et al. “Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial”. Clinical Infectious Diseases 24 (1997): 324-333. https://europepmc.org/article/med/9114180
    33. Moore SC. “Clostridium difficile: more challenging than ever”. Critical Care Nursing Clinics of North America 30 (2018): 41-53. https://pubmed.ncbi.nlm.nih.gov/29413214/
    34. Bartlett JG. “Detection of Clostridium difficile infection”. Infection Control and Hospital Epidemiology 31 (2010): 35-37. https://pubmed.ncbi.nlm.nih.gov/20929365/
    35. Crobach MJT., et al. “European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection”. Clinical Microbiology and Infection 22 (2016): S63-S81. https://pubmed.ncbi.nlm.nih.gov/27460910/
    36. American Academy of Pediatrics, Committee on Infectious Diseases. Red Book, 28th Edition. 2009 Report of the Committee on Infectious Diseases (2009): 263-265.
    37. Sethi AK., et al. “Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection”. Infection Control and Hospital Epidemiology 31 (2010): 21-27. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/persistence-of-skin-contamination-and-environmental-shedding-of-clostridium-difficile-during-and-after-treatment-of-c-difficile-infection/F3837ED70100D3FCBB7FB374DE2B24C6
    38. Goodhand JR., et al. “Systematic review: Clostridium difficile and inflammatory bowel disease”. Alimentary Pharmacology and Therapeutics 33 (2011): 428-441. https://pubmed.ncbi.nlm.nih.gov/21198703/
    39. Farooq PD., et al. “Pseudomembranous colitis”. Disease-A-Month 61 (2015): 181-206. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402243/
    40. Vaishnavi C. “Clinical spectrum and pathogenesis of Clostridium difficile associated diseases”. Indian Journal of Medical Research 131 (2010): 487-499. https://pubmed.ncbi.nlm.nih.gov/20424299/
    41. Paláu-Dávila L., et al. “Efficacy of computed tomography for the prediction of colectomy and mortality in patients with Clostridium difficile infection”. Annals of Medicine and Surgery 12 (2016): 101-105. https://pubmed.ncbi.nlm.nih.gov/27942384/
    42. Debast SB., et al. “ESCMID European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection”. Clinical Microbiology and Infection 20 (2014): 1-26. https://pubmed.ncbi.nlm.nih.gov/24118601/
    43. Johnson S., et al. “Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials”. Clinical Infectious Diseases 59 (2014): 345-354. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00998692/full
    44. Nelson RL., et al. “Antibiotic treatment for Clostridium difficile associated diarrhoea in adults”. Cochrane Database of Systematic Reviews 3 (2017): CD004610. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464548/
    45. Cornely OA., et al. “Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial”. The Lancet Infectious Diseases 12 (2012): 281-289. https://pubmed.ncbi.nlm.nih.gov/22321770/
    46. Cornely OA., et al. “Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin”. Clinical Infectious Diseases 55 (2012): S154-S161. https://www.researchgate.net/publication/228328988_Treatment_of_First_Recurrence_of_Clostridium_difficile_Infection_Fidaxomicin_Versus_Vancomycin
    47. Cornely OA., et al. “Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison”. Journal of Antimicrobial Chemotherapy 69 (2014): 2892e900. https://www.researchgate.net/publication/264396554_Clinical_efficacy_of_fidaxomicin_compared_with_vancomycin_and_metronidazole_in_Clostridium_difficile_infections_a_meta-analysis_and_indirect_treatment_comparison
    48. Czepiel J., et al. “The presence of IL-8 +781 T/C polymorphism is associated with the parameters of severe Clostridium difficile infection”. Microbial Pathogenesis 114 (2018): 281-285. https://pubmed.ncbi.nlm.nih.gov/29203364/
    49. Gerding DN and Johnson S. “Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI”. Nature Reviews Gastroenterology and Hepatology 8 (2011): 67-68. https://pubmed.ncbi.nlm.nih.gov/21293502/
    50. Evans CT and Johnson S. “Prevention of Clostridium difficile infection with probiotics”. Clinical Infectious Diseases 60 (2015): 122-128. https://pubmed.ncbi.nlm.nih.gov/25922397/
    51. Siddiqui F., et al. “Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive Clostridium difficile but does not prevent colonization”. The Journal of Infectious Diseases 205 (2012): 128-133. https://pubmed.ncbi.nlm.nih.gov/22124129/
    52. Wilcox MH., et al. “Bezlotoxumab for prevention of recurrent Clostridium difficile infection”. The New England Journal of Medicine 376 (2017): 305-317. https://www.nejm.org/doi/full/10.1056/nejmoa1602615
    53. Zhang F., et al. “Should we standardize the 1700 year old fecal microbiota transplantation?” The American Journal of Gastroenterology 107 (2012): 755. https://journals.lww.com/ajg/Citation/2012/11000/Should_We_Standardize_the_1,700_Year_Old_Fecal.26.aspx
    54. Borody TJ., et al. “Bacteriotherapy using fecal flora: toying with human motions”. Journal of Clinical Gastroenterology 38 (2004): 475-483. https://pubmed.ncbi.nlm.nih.gov/15220681/
    55. Eiseman B., et al. “Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis”. Surgery 44 (1958): 854-859. https://pubmed.ncbi.nlm.nih.gov/13592638/
    56. Schwan A., et al. “Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces”. Lancet 2 (1983): 845. https://pubmed.ncbi.nlm.nih.gov/6137662/
    57. Terveer EM., et al. “How to: Establish and run a stool bank”. Clinical Microbiology and Infection 12 (2017): 924-930. https://pubmed.ncbi.nlm.nih.gov/28529025/
    58. Rao K and Young VB. “Fecal microbiota transplantation for the management of Clostridium difficile infection”. Infectious Disease Clinics of North America 1 (2015): 109-122. https://pubmed.ncbi.nlm.nih.gov/25677705/
    59. Keller PM and Weber MH. “Rational Therapy of Clostridium difficile Infections”. Viszeralmedizin5 (2014): 304-309. https://www.karger.com/Article/FullText/366302
    60. Singh T., et al. “Updates in Treatment of Recurrent Clostridium difficile Infection”. Journal of Clinical Medicine Research 7 (2019): 465-471. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6575119/
    61. Balsells E., et al. “Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations”. Journal of Global Health 2 (2016): 020410. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5140074/
    62. WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. Geneva: World Health Organization. Appendix 2, Guide to appropriate hand hygiene in connection with Clostridium difficile spread (2009). https://www.who.int/gpsc/5may/tools/who_guidelines-handhygiene_summary.pdf
    63. McDonald LC., et al. “Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)”. Clinical Infectious Diseases 7 (2018): e1-e48. https://pubmed.ncbi.nlm.nih.gov/29462280/
    64. Boyce JM., et al. “Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting”. Infection Control and Hospital Epidemiology 8 (2008): 723-729. https://pubmed.ncbi.nlm.nih.gov/18636950/
Citation: Kerna NA, Flores JV, Holets HM, Akabike LU, Chen MH, Solomon EO, Pruitt KD, Nwokorie U, Waugh S. “Causes, Consequences, and Cures of Clostridium difficile Infection”. EC Gastroenterology and Digestive System 8.2 (2021): 136-148.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before April 26, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk